Antiretroviral blood levels in HIV/HCV‐coinfected patients with cirrhosis after liver transplant: a report of three cases. Issue 1 (12th January 2015)

• Record Type: Journal Article
• Authors: Righi, E.; Londero, A.; Pea, F.; Bonora, S.; Nasta, P.; Della Siega, P.; Delle Foglie, P.; Villa, G.; Giglio, O.; Dal Zoppo, S.; Baccarani, U.; Bassetti, M.
• Is Part Of: Transplant infectious disease. Volume 17:Issue 1(2015)
• Page Start: 147
• Page End: 153
• Publication Date: 2015-01-12
• Subjects: Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12339
• Languages: English
• ISSNs: 1398-2273

Abstract

<abstract abstract-type="main" id="tid12339-abs-0001"> <title>Abstract</title> <p>Since the introduction of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection is no longer a contraindication for solid organ transplantation. In HIV/hepatitis C virus (HCV)‐coinfected patients undergoing liver transplantation, HCV‐related cirrhosis, drug‐drug interactions, and calcineurin inhibitors‐related toxicity affect clinical outcomes. Therapeutic drug monitoring can be useful to assess antiretroviral over‐ or underexposure in this cohort. We report the clinical characteristics along with antiretroviral trough levels of maraviroc, darunavir, and etravirine in 3 HIV/HCV‐coinfected liver transplant recipients who developed post‐transplant liver cirrhosis.</p> </abstract>